Table 3 Baseline clinical and demographic data for all enrolled participants: (A) Ekso group baseline clinical characteristics, (B) Active Control group baseline clinical characteristics, and (C) Passive Control group baseline clinical characteristics.

From: Walking improvement in chronic incomplete spinal cord injury with exoskeleton robotic training (WISE): a randomized controlled trial

Subject ID

Gender

Age (yrs)

Time since injury (yrs)

AIS

ISNCSCI (motor) (L-R)

ISNCSCI (sensory) (L-R)

WISCI-II

SCI-FAI

SCIM-III

LEMS

UEMS

SCATS (clonus) (L-R)

SCI-SET Total Score

Gait speed (SS, m/s)

(A)

              

01-123a

F

41

22.3

C

T1-T2

T2-C8

12

2

13

14

50

2-2

0.00

0.18

02-108a,b

M

26

7.8

C

L1

T10-L4

12

3

17

19

50

0-0

−0.11

0.34

02-115a,b,c

F

38

2.1

C

T11

T11

19

5

33

23

50

0-2

−1.00

0.41

02-1271

M

48

8.0

D

C3-C6

C3-C4

16

4

21

37

37

2-2

−1.20

0.22

02-130a,b

M

48

28.5

D

C6-T1

C7-C4

19

5

33

40

47

1-1

−0.63

0.43

02-132

M

37

2.3

D

C6-C7

C6-T8

6

1

7

28

38

1-1

−0.29

0.38

04-1061

F

35

9.3

C

T1

T1

9

3

17

20

50

1-1

−0.50

0.16

07-1081

M

58

7.2

D

C5-C7

C5-T10

13

3

16

22

28

1-1

0.00

0.34

07-110a,b,c

F

48

1.2

D

T1-C7

C4

12

4

30

45

48

1-0

−1.42

0.26

08-105a,b,d

F

46

8.1

C

C7

T2

13

3

20

26

32

1-1

−0.53

0.42

09-106

M

34

1.6

C

T7-T6

T7-T6

6

1

17

17

50

1-1

−0.35

0.09

09-108

M

41

2.4

D

C5-C3

C5-C3

8

2

6

36

32

2-2

−1.60

(B)

              

01-115a,d

F

61

C

L1–T10

L1-T10

16

4

19

7

50

0-0

−0.49

0.24

02-109a,d

F

28

2.8

D

T5-T7

T5-T7

19

4

31

42

50

0-0

−0.29

0.30

02-114a

F

34

10.4

C

L1

C6-L1

6

2

17

11

50

0-0

−2.63

0.09

02-118a

M

56

10.5

D

T1

C7-C6

19

4

25

24

50

1-1

−0.31

0.35

02-125a

M

56

8.8

C

C7–C6

C7-C6

13

2

5

23

28

0-0

−0.26

0.16

04-103a

M

65

2.3

D

T1

C8-T1

13

4

21

38

50

1-1

−0.12

0.30

04-104a

M

52

12.3

D

C3

C3

18

4

23

33

36

1-1

−0.41

0.26

07-107a

F

62

4.2

D

C1

C1

6

2

12

50

48

1-1

−2.47

0.16

08-103a

M

31

6.2

D

C1

C4-C8

13

4

19

39

50

0-0

−0.09

0.17

08-106

F

64

14.2

D

T12-L2

T12-L1

16

5

29

44

50

0-0

−0.22

0.48

09-104

F

43

3.6

D

C5

C4

13

1

4

36

14

2–2

−1.12

0.03

09-105a,c

M

71

2.1

D

C5

T7-T4

13

5

20

47

40

0-0

−0.44

0.35

(C)

              

01-116a

M

74

1.7

D

C7

L4-L3

9

3

22

45

46

1-0

−0.14

0.17

02-112a

M

59

10.0

D

C7

C5

16

5

30

41

36

0-1

−0.94

0.34

02-129a

M

45

11.0

D

C3-C2

C3-C2

6

3

19

18

50

0-0

−0.56

013

07-105a

F

59

1.3

D

C3-C7

C3-T1

13

3

16

43

44

0-0

−0.09

0.33

08-104a

M

26

1.2

D

T4

T5-T4

13

2

19

35

50

1-1

−0.12

0.12

09-107a

M

31

1.0

D

C6–C7

T9

13

3

17

33

34

1-1

−0.23

0.24

  1. Baseline clinical and demographic data for all enrolled participants in (A) Ekso, (B) Active Control and (C) Passive Control groups. Baseline characteristics were comparable across all treatment groups.
  2. AIS ASIA Impairment Scale, ASIA (American Spinal Injury Association), ISNCSCI International Standard for Neurological Classification of Spinal Cord Injury, WISCI-II Walking Index for Spinal Cord Injury, SCI-FAI Spinal Cord Injury Functional Ambulation Index, SCIM-III Spinal Cord Independence Measure, LEMS Lower Extremity Motor Score, UEMS Upper Extremity Motor Score, SCATS Spinal Cord Assessment Tool for Spastic Reflexes, SCI-SET Spinal Cord Injury Spasticity Evaluation Tool, SS self-selected.
  3. aPer Protocol Group.
  4. bResponder to > 0.44  m/s threshold.
  5. cResponder to MCID threshold.
  6. dResponder to both thresholds.